Aurinia Pharmaceuticals (AUPH) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Aurinia Pharmaceuticals Inc. presented new data at ASN Kidney Week 2024, highlighting the effectiveness of LUPKYNIS in treating lupus nephritis, particularly in diverse populations most affected by the disease. Real-world data showcased LUPKYNIS’s positive impact on kidney health compared to older therapies, with studies indicating improved outcomes and stronger podocyte stability at lower doses.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.